( Tokyo:4565 )

News from Heptares Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

18 May, 2017, 03:00 ET Heptares' Co-Founder and Chief Scientific Officer, Fiona Marshall, Receives 2017 John Daly Lecture Award in Recognition of Her Outstanding Contribution to GPCR Drug Discovery

Heptares Therapeutics ("Heptares"), the leading GPCR medicine design and development company and wholly-owned subsidiary of Sosei Group...


18 May, 2017, 03:00 ET Heptares to Receive US$5 Million Milestone Payment From Teva

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), has been notified by...


27 Apr, 2017, 02:30 ET Heptares Collaboration With AstraZeneca Yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation

Novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules - research published in Nature...


05 Apr, 2017, 02:35 ET Heptares To Receive US$12 Million Milestone Payment From AstraZeneca

- AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity...


13 Mar, 2017, 03:05 ET Heptares Therapeutics Enters Agreement With Daiichi Sankyo to Discover and Develop Novel, Small-molecules for the Treatment of Pain

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces that it has...


31 Jan, 2017, 04:21 ET Heptares Enters a New Research Collaboration Under Its 'Orbit' Initiative With the University of Cambridge

New Programme Focused on Apelin Receptor in Cardiovascular Diseases Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei...


08 Dec, 2016, 03:00 ET Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family

Chemokine receptor family plays key role across multiple disease areas and represents an important target for drug discovery and development...


29 Nov, 2016, 19:15 ET Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has signed a...


06 Jul, 2016, 02:42 ET Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has been...


29 Jun, 2016, 04:00 ET Heptares and Leadxpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and leadXpro AG...


28 Apr, 2016, 05:05 ET Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that Dr Fiona...


25 Apr, 2016, 11:05 ET Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease

  First structure of GLP-1 receptor in active state resolved   Novel allosteric binding site in glucagon receptor identified -...


10 Feb, 2016, 01:30 ET Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity   Heptares Therapeutics ("Heptares"), the...


02 Feb, 2016, 04:00 ET Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS)

First collaboration initiated with Imperial College London  Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group...


30 Nov, 2015, 05:00 ET Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

Heptares Therapeutics ("Heptares"), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of...


23 Jan, 2015, 04:00 ET Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm...


08 Jan, 2015, 04:00 ET Heptares Adds Experts in Drug Discovery and Development to its Board of Directors

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is pleased to announce the appointments of...


06 Jan, 2015, 04:00 ET Heptares to Present at Upcoming East/West CEO Conference

Heptares Therapeutics, the clinical-stage GPCR drug discovery and development company, notes that members of its senior management team will...


15 Dec, 2014, 04:00 ET Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce the grant of multiple key...


20 Nov, 2014, 10:16 ET Heptares Orphan Disease Programme Awarded Grant from the UK Biomedical Catalyst

  Project to develop first-in-class selective and orally available GLP-1 receptor antagonist for treating severe hypoglycaemia (low blood...


17 Nov, 2014, 04:00 ET Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch

Program to be presented at Therapeutic Area Partnerships Conference in Boston on 20 November   Heptares Therapeutics, the leading GPCR...


16 Sep, 2014, 04:00 ET Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium

Heptares Therapeutics notes that its Chief Scientific Officer, Fiona Marshall, will give a presentation entitled "Structure-based Drug Design...


07 Jul, 2014, 04:00 ET Heptares Announces Publication in Nature of First Structure of Metabotropic Glutamate Receptor 5 Transmembrane Domain

Heptares has solved structures across all major GPCR families (A, B and C) providing platforms for wide-ranging structure-based and antibody drug...


30 Jun, 2014, 04:00 ET Heptares' Chief Scientific Officer and Co-Founder Fiona Marshall to Present at Royal Society of Medicine Medical Innovations Summit

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall,...


24 Jun, 2014, 13:00 ET Heptares to Present at JMP Securities Healthcare Conference

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will...